Vanguard Group Inc Supernus Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,163,892 shares of SUPN stock, worth $205 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,163,892
Previous 6,150,759
0.21%
Holding current value
$205 Million
Previous $222 Million
9.24%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$346 Million0.01% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$173 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$96.6 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$89.8 Million0.11% of portfolio
-
State Street Corp Boston, MA2.15MShares$71.4 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.78B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...